Immediate action needed to improve labeling of prescription drugs for pediatric patients

被引：10

作者：

Kearns, GL

Reed, MD

机构：

[1] RAINBOW BABIES & CHILDRENS HOSP,PEDIAT PHARMACOL DIV,CLEVELAND,OH 44106

[2] UNIV MISSOURI,KANSAS CITY,MO 64110

[3] CHILDRENS MERCY HOSP,SECT PEDIAT CLIN PHARMACOL & EXPT THERAPEUT,KANSAS CITY,MO 64108

[4] CHILDRENS MERCY HOSP,PEDIAT PHARMACOL RES UNIT,KANSAS CITY,MO 64108

[5] CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH 44106

来源：

ANNALS OF PHARMACOTHERAPY | 1997年 / 31卷 / 02期

关键词：

D O I：

10.1177/106002809703100220

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

收藏

页码：249 / 251

页数：3

相关论文

共 9 条

[1] Farrar HC, 1996, EXPERT OPIN INV DRUG, V5, P7
[2] PHARMACOKINETIC STUDIES IN PEDIATRIC-PATIENTS - CLINICAL AND ETHICAL CONSIDERATIONS
KAUFFMAN, RE
KEARNS, GL
[J]. CLINICAL PHARMACOKINETICS, 1992, 23 (01) : 10 - 29
[3] CLINICAL PHARMACOKINETICS IN INFANTS AND CHILDREN - A REAPPRAISAL
KEARNS, GL
REED, MD
[J]. CLINICAL PHARMACOKINETICS, 1989, 17 : 29 - 67
[4] Kearns Gregory L., 1995, Current Opinion in Pediatrics, V7, P220, DOI 10.1097/00008480-199504000-00018
[5] New regulations for pediatric labeling of prescription drugs
Nahata, MC
[J]. ANNALS OF PHARMACOTHERAPY, 1996, 30 (09) : 1032 - 1033
[6] REED MD, 1989, PEDIATR CLIN N AM, V36, P1053
[7] MECHANISMS OF UNPREDICTABLE ADVERSE DRUG-REACTIONS
RIEDER, MJ
[J]. DRUG SAFETY, 1994, 11 (03) : 196 - 212
[8] EDITORIAL COMMENT - THERAPEUTIC ORPHANS
SHIRKEY, H
[J]. JOURNAL OF PEDIATRICS, 1968, 72 (01) : 119 - +
[9] PEDIATRIC LABELING REQUIREMENTS - IMPLICATIONS FOR PHARMACOKINETIC STUDIES
WILSON, JT
KEARNS, GL
MURPHY, D
YAFFE, SJ
[J]. CLINICAL PHARMACOKINETICS, 1994, 26 (04) : 308 - 325